Literature DB >> 2881218

Alpha-adrenoceptor activity of arylalkylimidazoles is improved by alpha-methylation and impaired by alpha-hydroxylation.

J M Savola.   

Abstract

To investigate the effects of hydroxyl and methyl substitution of the alkyl bridge bond on the alpha-adrenoceptor activity of arylalkylimidazole derivatives, the cardiovascular effects of the molecules were studied in anaesthetized and pithed rats. The compounds studied were 4(5)-substituted imidazole derivatives with a methano, ethano or etheno bridge between the imidazole and the 2-, 2,3- or 2,6-methyl substituted phenyl rings. The hypotensive and bradycardic activities of the molecules in the anaesthetized rat were always reduced by alpha-hydroxylation and usually augmented by alpha-methylation of the bridge between the imidazole and phenyl rings. Hydroxylation was associated with a consistent, marked decrease in vasopressor and sympatho-inhibitory activity in the cardiovascular system of the pithed rat, but a methyl moiety as a "bulky substituent" in the alpha-position of the alkyl bridge did not decrease but even caused an increase in alpha-adrenoceptor activity in this test system. The detrimental effect of alpha-hydroxylation of the compounds at alpha 1- and alpha 2-adrenoceptors supports the notion that the interaction of the imidazoles at alpha-adrenoceptor is different from that of the classical, noradrenaline-like phenethylamines. The results also suggest that the alkyl bridge between the phenyl and imidazole rings of the imidazoles may contribute directly to the binding process.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2881218     DOI: 10.1007/bf00569381

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  29 in total

Review 1.  Interactions of agonists with peripheral alpha-adrenergic receptors.

Authors:  R R Ruffolo
Journal:  Fed Proc       Date:  1984-11

2.  The cardiovascular effects of MPV 295 [4(5)-2-(2,6-dimethylphenyl)ethylimidazole], a new antihypertensive agent with alpha 2-adrenoceptor agonistic properties.

Authors:  H Ruskoaho; J M Savola; S Kaipiainen; J Puurunen; N Kärki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-05       Impact factor: 3.000

Review 3.  Alpha-adrenoceptor subclassification.

Authors:  K Starke
Journal:  Rev Physiol Biochem Pharmacol       Date:  1981       Impact factor: 5.545

4.  Stereochemical requirements of alpha-2 adrenergic receptors.

Authors:  R R Ruffolo; E L Yaden; J E Waddell
Journal:  J Pharmacol Exp Ther       Date:  1982-09       Impact factor: 4.030

5.  Quantum mechanical study of the conformational properties of phenethylamines of biochemical and medicinal interest.

Authors:  B Pullman; J L Coubeils; P Courrière; J P Gervois
Journal:  J Med Chem       Date:  1972-01       Impact factor: 7.446

6.  Central hypotensive and antihypertensive activities of imidazolidines, structurally related to clonidine.

Authors:  P B Timmermans; P A Van Zwieten
Journal:  Arch Int Pharmacodyn Ther       Date:  1977-08

7.  A study of the selectivity and potency of rauwolscine, RX 781094 and RS 21361 as antagonists of alpha-1 and alpha-2 adrenoceptors.

Authors:  P B Timmermans; J Q Qian; R R Ruffolo; P A van Zwieten
Journal:  J Pharmacol Exp Ther       Date:  1984-03       Impact factor: 4.030

8.  Studies on RX 781094: a selective, potent and specific antagonist of alpha 2-adrenoceptors.

Authors:  J C Doxey; A G Roach; C F Smith
Journal:  Br J Pharmacol       Date:  1983-03       Impact factor: 8.739

9.  Receptor interactrions of imidazolines. VI. Significance of carbon bridge separating phenyl and imidazoline rings of tolazoline-like alpha adrenergic imidazolines.

Authors:  R R Ruffolo; E L Yaden; J E Waddell; R D Dillard
Journal:  J Pharmacol Exp Ther       Date:  1980-09       Impact factor: 4.030

10.  Characterization of alpha-adrenoceptor populations. Quantitative relationships between cardiovascular effects initiated at central and peripheral alpha-adrenoceptors.

Authors:  P B Timmermans; A de Jonge; J C van Meel; F P Slothorst-Grisdijk; E Lam; P A van Zwieten
Journal:  J Med Chem       Date:  1981-05       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.